Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.3.98.1 - dihydroorotate dehydrogenase (fumarate)

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Arthritis
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Lapachol, a compound targeting pyrimidine metabolism, ameliorates experimental autoimmune arthritis.
Arthritis, Rheumatoid
Association of DHODH haplotype variants and response to leflunomide treatment in rheumatoid arthritis.
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Dual binding mode of a novel series of DHODH inhibitors.
Human dihydroorotate dehydrogenase inhibitors, a novel approach for the treatment of autoimmune and inflammatory diseases.
Precision Medicine with Leflunomide: Consideration of DHODH Haplotype and Plasma Teriflunomide Concentration can Substantially Modify Outcomes in Patients with Rheumatoid Arthritis.
Preparation of human dihydroorotate dehydrogenase for interaction studies with lipid bilayers.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Autoimmune Diseases
4SC-101, a novel immunosuppressive drug, inhibits IL-17 and attenuates colitis in two murine models of inflammatory bowel disease.
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Fluorine modulates species selectivity in the triazolopyrimidine class of Plasmodium falciparum dihydroorotate dehydrogenase inhibitors.
IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro.
Natural product piperine alleviates experimental allergic encephalomyelitis in mice by targeting dihydroorotate dehydrogenase.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
Breast Neoplasms
Cis-eQTL-based trans-ethnic meta-analysis reveals novel genes associated with breast cancer risk.
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Carcinogenesis
Energy Metabolism Rewiring Precedes UVB-Induced Primary Skin Tumor Formation.
Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells.
Carcinoma
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Dihydroorotate dehydrogenase is required for N-(4-hydroxyphenyl)retinamide-induced reactive oxygen species production and apoptosis.
Elevated DHODH expression promotes cell proliferation via stabilizing ?-catenin in esophageal squamous cell carcinoma.
The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III.
Chagas Disease
Computational study of the mechanism of half-reactions in class 1A dihydroorotate dehydrogenase from Trypanosoma cruzi.
Colorectal Neoplasms
PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis.
COVID-19
A comprehensive drug repurposing study for COVID19 treatment: novel putative dihydroorotate dehydrogenase inhibitors show association to serotonin-dopamine receptors.
A Small-Scale Medication of Leflunomide as a Treatment of COVID-19 in an Open-Label Blank-Controlled Clinical Trial.
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Cysts
Expression of the dihydroorotate dehydrogenase gene, dhod, during spermatogenesis in Drosophila melanogaster.
dihydroorotate dehydrogenase (fumarate) deficiency
Elevated plasma dihydroorotate in Miller syndrome: Biochemical, diagnostic and clinical implications, and treatment with uridine.
Dysostoses
Miller (Genee-Wiedemann) syndrome represents a clinically and biochemically distinct subgroup of postaxial acrofacial dysostosis associated with partial deficiency of DHODH.
Mitochondrial nucleic acid binding proteins associated with diseases.
Targeted Next-Generation Sequencing in the Diagnosis of Facial Dysostoses.
Esophageal Squamous Cell Carcinoma
Elevated DHODH expression promotes cell proliferation via stabilizing ?-catenin in esophageal squamous cell carcinoma.
Foot-and-Mouth Disease
Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus.
Genetic Diseases, Inborn
Preparation of human dihydroorotate dehydrogenase for interaction studies with lipid bilayers.
Glioblastoma
Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
The transcription factors aryl hydrocarbon receptor and MYC cooperate in the regulation of cellular metabolism.
Glioma
Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Hematologic Neoplasms
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
Targeting of Hematologic Malignancies with PTC299, A Novel Potent Inhibitor of Dihydroorotate Dehydrogenase with Favorable Pharmaceutical Properties.
Herpes Simplex
Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication.
Hypersensitivity
Synthesis, structure-activity relationships, and pharmacokinetic properties of dihydroorotate dehydrogenase inhibitors: 2-cyano-3-cyclopropyl-3-hydroxy-N-[3'-methyl-4'-(trifluoromethyl)phenyl ] propenamide and related compounds.
Infections
In vitro selection predicts malaria parasite resistance to dihydroorotate dehydrogenase inhibitors in a mouse infection model.
Influenza, Human
Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors "leflunomide" and "teriflunomide" in Covid-19: A narrative review.
Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2.
Leishmaniasis
Crystal structure of dihydroorotate dehydrogenase from Leishmania major.
Natural products as inhibitors of Leishmania major dihydroorotate dehydrogenase.
Leishmaniasis, Cutaneous
Crystal structure of dihydroorotate dehydrogenase from Leishmania major.
Leukemia
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Leukemia, Myeloid
A combined Chemical, Computational and invitro approach identifies SBL 105 as novel DHODH inhibitor in Acute Myeloid Leukemia cells.
Leukemia, Myeloid, Acute
A combined Chemical, Computational and invitro approach identifies SBL 105 as novel DHODH inhibitor in Acute Myeloid Leukemia cells.
Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia.
DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia.
Lung Neoplasms
Identification of DHODH as a therapeutic target in small cell lung cancer.
Lymphocytic Choriomeningitis
Novel Dihydroorotate Dehydrogenase Inhibitors with Potent Interferon-Independent Antiviral Activity against Mammarenaviruses In Vitro.
Lymphoma
Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
Malaria
A high-throughput fluorescence-based assay for Plasmodium dihydroorotate dehydrogenase inhibitor screening.
A long-duration dihydroorotate dehydrogenase inhibitor (DSM265) for prevention and treatment of malaria.
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Optimization of Potent Inhibitors of P. falciparum Dihydroorotate Dehydrogenase for the Treatment of Malaria.
Potent Antimalarials with Development Potential Identified by Structure-Guided Computational Optimization of a Pyrrole-Based Dihydroorotate Dehydrogenase Inhibitor Series.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Structural basis for the function and inhibition of dihydroorotate dehydrogenase from Schistosoma mansoni.
Synthesis of brequinar analogue inhibitors of malaria parasite dihydroorotate dehydrogenase.
Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines Targeting Plasmodium falciparum Dihydroorotate Dehydrogenase Display Potent and Selective Antimalarial Activity.
The X-ray structure of Plasmodium falciparum dihydroorotate dehydrogenase bound to a potent and selective N-phenylbenzamide inhibitor reveals novel binding-site interactions.
Mandibulofacial Dysostosis
Targeted Next-Generation Sequencing in the Diagnosis of Facial Dysostoses.
Measles
Original 2-(3-Alkoxy-1H-pyrazol-1-yl)azines Inhibitors of Human Dihydroorotate Dehydrogenase (DHODH).
Melanoma
Computational and experimental prediction of molecules involved in the anti-melanoma action of berberine.
DHODH modulates transcriptional elongation in the neural crest and melanoma.
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Inactivation/deficiency of DHODH induces cell cycle arrest and programed cell death in melanoma.
Synergistic inhibition of melanoma xenografts by Brequinar sodium and Doxorubicin.
The aryl hydrocarbon receptor mediates leflunomide-induced growth inhibition of melanoma cells.
Metabolism, Inborn Errors
Choline-related-inherited metabolic diseases-A mini review.
Mouth Diseases
Antiviral effects of selected IMPDH and DHODH inhibitors against foot and mouth disease virus.
Multiple Myeloma
Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Multiple Sclerosis
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Preparation of human dihydroorotate dehydrogenase for interaction studies with lipid bilayers.
Multiple Sclerosis, Relapsing-Remitting
Vidofludimus calcium, a next generation DHODH inhibitor for the Treatment of relapsing-remitting multiple sclerosis.
Myelodysplastic Syndromes
DHODH inhibition synergizes with DNA-demethylating agents in the treatment of myelodysplastic syndromes.
Neoplasm Metastasis
PCK1 and DHODH drive colorectal cancer liver metastatic colonization and hypoxic growth by promoting nucleotide synthesis.
Neoplasms
A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Checkpoint kinase 1 inhibition sensitises transformed cells to dihydroorotate dehydrogenase inhibition.
Dependence on the Pyrimidine Biosynthetic Enzyme DHODH Is a Synthetic Lethal Vulnerability in Mutant KRAS-Driven Cancers.
Design, Synthesis, and Characterization of Brequinar Conjugates as Probes to Study DHODH Inhibition.
DHODH and cancer: promising prospects to be explored.
DHODH inhibition modulates glucose metabolism and circulating GDF15, and improves metabolic balance.
DHODH-mediated ferroptosis defence is a targetable vulnerability in cancer.
Dihydroorotate dehydrogenase (DHODH) inhibitors affect ATP depletion, endogenous ROS and mediate S-phase arrest in breast cancer cells.
Dihydroorotate dehydrogenase in oxidative phosphorylation and cancer.
Dihydroorotate Dehydrogenase Inhibitors Promote Cell Cycle Arrest and Disrupt Mitochondria Bioenergetics in Ramos Cells.
Dihydroorotate dehydrogenase Inhibitors Target c-Myc and Arrest Melanoma, Myeloma and Lymphoma cells at S-phase.
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.
Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia.
Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells.
Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis.
Metabolomics profiles delineate uridine deficiency contributes to mitochondria-mediated apoptosis induced by celastrol in human acute promyelocytic leukemia cells.
Mitochondrial ubiquinol oxidation is necessary for tumour growth.
Optimization of Tetrahydroindazoles as Inhibitors of Human Dihydroorotate Dehydrogenase and Evaluation of Their Activity and In Vitro Metabolic Stability.
Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.
Quantitation of uridine and L-dihydroorotic acid in human plasma by LC-MS/MS using a surrogate matrix approach.
Reactivation of Dihydroorotate Dehydrogenase-Driven Pyrimidine Biosynthesis Restores Tumor Growth of Respiration-Deficient Cancer Cells.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Revisiting the role of dihydroorotate dehydrogenase as a therapeutic target for cancer.
Selective Vulnerability to Pyrimidine Starvation in Hematologic Malignancies Revealed by AG-636, a Novel Clinical-Stage Inhibitor of Dihydroorotate Dehydrogenase.
SOX2-dependent expression of dihydroorotate dehydrogenase regulates oral squamous cell carcinoma cell proliferation.
Structures of human dihydroorotate dehydrogenase in complex with antiproliferative agents.
The pathway to pyrimidines: The essential focus on dihydroorotate dehydrogenase, the mitochondrial enzyme coupled to the respiratory chain.
The Role of Dihydroorotate Dehydrogenase in Apoptosis Induction in Response to Inhibition of the Mitochondrial Respiratory Chain Complex III.
The Synergism between DHODH Inhibitors and Dipyridamole Leads to Metabolic Lethality in Acute Myeloid Leukemia.
Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis.
Neuroblastoma
Leflunomide reduces proliferation and induces apoptosis in neuroblastoma cells in vitro and in vivo.
Therapeutic targeting of both dihydroorotate dehydrogenase and nucleoside transport in MYCN-amplified neuroblastoma.
Oral Ulcer
Non-healing tongue ulcer in a rheumatoid arthritis patient medicated with leflunomide. An adverse drug event?
Parasitic Diseases
Use of human Dihydroorotate Dehydrogenase (hDHODH) Inhibitors in Autoimmune Diseases and New Perspectives in Cancer Therapy.
Psoriasis
Evaluation of WO2013076170: the use of a dihydroorotate dehydrogenase inhibitor for the treatment of psoriasis.
Recent Developments in the Medicinal Chemistry and Therapeutic Potential of Dihydroorotate Dehydrogenase (DHODH) Inhibitors.
Schistosomiasis
Structural basis for the design of selective inhibitors for Schistosoma mansoni dihydroorotate dehydrogenase.
Skin Neoplasms
UVB-induced DHODH upregulation, which is driven by STAT3, is a promising target for chemoprevention and combination therapy of photocarcinogenesis.
Small Cell Lung Carcinoma
Identification of DHODH as a therapeutic target in small cell lung cancer.
Vesicular Stomatitis
Inhibiting pyrimidine biosynthesis impairs Ebola virus replication through depletion of nucleoside pools and activation of innate immune responses.
Inhibition of pyrimidine synthesis reverses viral virulence factor-mediated block of mRNA nuclear export.
Virus Diseases
Dihydroorotate dehydrogenase: A drug target for the development of antimalarials.